1 | intervals | 11,430 |
2 | acid-schiff | 31 |
3 | elapsing | 11 |
4 | choosers | 4 |
5 | alendronate/risedronate | 3 |
6 | internals | 3 |
7 | weigh-ins | 3 |
8 | ca-al-co | 2 |
9 | holters | 2 |
10 | leukocidine | 2 |
11 | stand-ups | 2 |
12 | 'cc | 1 |
13 | 'tc | 1 |
14 | 0–t | 1 |
15 | 1'-o- | 1 |
16 | 201tl-stress | 1 |
17 | 253,44±51,51minutes | 1 |
18 | acaloric | 1 |
19 | acid-methenamine-silver | 1 |
20 | acid/schiff | 1 |
21 | alpha-pregnan-3-one | 1 |
22 | amaronitidin | 1 |
23 | asynergies | 1 |
24 | at.lantus | 1 |
25 | auc-gir | 1 |
26 | ca125/muc16 | 1 |
27 | classes/week | 1 |
28 | cytokine/fasting | 1 |
29 | dexamethasone.experience | 1 |
30 | disease-history | 1 |
31 | drinking-in-dark | 1 |
32 | dyspneas | 1 |
33 | ebm-teaching | 1 |
34 | edta-saline | 1 |
35 | euro-quality-of-life | 1 |
36 | grazing/standing | 1 |
37 | hall-walk-test | 1 |
38 | iii-complexes | 1 |
39 | indo-treated | 1 |
40 | integrales | 1 |
41 | interval-1.8 | 1 |
42 | interval-3.27 | 1 |
43 | interval.28 | 1 |
44 | interval.37 | 1 |
45 | interval.studies | 1 |
46 | interval/ | 1 |
47 | interval1.16 | 1 |
48 | interval:13.2 | 1 |
49 | interval:24 | 1 |
50 | interval=-0.08 | 1 |
51 | interval=-0.10 | 1 |
52 | interval=-0.29 | 1 |
53 | interval=-1.9 | 1 |
54 | interval=-13.3 | 1 |
55 | interval=-16.6 | 1 |
56 | interval=-3.4-2.1 | 1 |
57 | interval=-3.64 | 1 |
58 | interval=-4.41 | 1 |
59 | interval=-6.40 | 1 |
60 | interval=0.15 | 1 |
61 | interval=0.17-0.98 | 1 |
62 | interval=0.21 | 1 |
63 | interval=0.212-0.950 | 1 |
64 | interval=0.35 | 1 |
65 | interval=0.38 | 1 |
66 | interval=0.41 | 1 |
67 | interval=0.46 | 1 |
68 | interval=0.65 | 1 |
69 | interval=0.73 | 1 |
70 | interval=0.75-3.25 | 1 |
71 | interval=0.76 | 1 |
72 | interval=0.78-0.97 | 1 |
73 | interval=0.85-1.59 | 1 |
74 | interval=0.9-6.0 | 1 |
75 | interval=1 | 1 |
76 | interval=1.00-1.25 | 1 |
77 | interval=1.02 | 1 |
78 | interval=1.03-1.29 | 1 |
79 | interval=1.03-14.42 | 1 |
80 | interval=1.1-4.1 | 1 |
81 | interval=1.12-1.26 | 1 |
82 | interval=1.13-3.86 | 1 |
83 | interval=1.20-7.47 | 1 |
84 | interval=1.26 | 1 |
85 | interval=1.27-7.79 | 1 |
86 | interval=1.3-5 | 1 |
87 | interval=1.39 | 1 |
88 | interval=1.92-50.19 | 1 |
89 | interval=11-15 | 1 |
90 | interval=2.0 | 1 |
91 | interval=2.3-5.0 | 1 |
92 | interval=2.53-9.64 | 1 |
93 | interval=3 | 1 |
94 | interval=3.9 | 1 |
95 | interval=4.0 | 1 |
96 | interval=4.3 | 1 |
97 | interval=95 | 1 |
98 | intervals=-2 | 1 |
99 | intervals=-3 | 1 |
100 | intervals=0.30-0.80 | 1 |
101 | intervals=1.03-1.40 | 1 |
102 | intralipid/heparin-infusion | 1 |
103 | intrerval | 1 |
104 | irvt | 1 |
105 | isoload | 1 |
106 | kt2442-r2 | 1 |
107 | level-0.08 | 1 |
108 | nap-takers | 1 |
109 | nitrogen-hyperoxia | 1 |
110 | pattern/axis | 1 |
111 | phonophobia-free | 1 |
112 | photophobia-free | 1 |
113 | placebo-electrolyte | 1 |
114 | post-tasting | 1 |
115 | post-water | 1 |
116 | postpremedication | 1 |
117 | posttenecteplase | 1 |
118 | predictabilities | 1 |
119 | prolastin®-c | 1 |
120 | pvts | 1 |
121 | risk-adjustors | 1 |
122 | rotation/day | 1 |
123 | rpe-session | 1 |
124 | sulfamerazine/trimethoprime | 1 |
125 | thigh/buttock | 1 |
126 | trials-exercise | 1 |
127 | ttp/ttf | 1 |
128 | u-100 | 1 |
129 | vb_efas_gec-efs_3 | 1 |
130 | walk/jog | 1 |
131 | wii-intervention | 1 |
1 | 'cc | 1 |
2 | 'tc | 1 |
3 | 0–t | 1 |
4 | 1'-o- | 1 |
5 | 201tl-stress | 1 |
6 | 253,44±51,51minutes | 1 |
7 | acaloric | 1 |
8 | acid-methenamine-silver | 1 |
9 | acid-schiff | 31 |
10 | acid/schiff | 1 |
11 | alendronate/risedronate | 3 |
12 | alpha-pregnan-3-one | 1 |
13 | amaronitidin | 1 |
14 | asynergies | 1 |
15 | at.lantus | 1 |
16 | auc-gir | 1 |
17 | ca-al-co | 2 |
18 | ca125/muc16 | 1 |
19 | choosers | 4 |
20 | classes/week | 1 |
21 | cytokine/fasting | 1 |
22 | dexamethasone.experience | 1 |
23 | disease-history | 1 |
24 | drinking-in-dark | 1 |
25 | dyspneas | 1 |
26 | ebm-teaching | 1 |
27 | edta-saline | 1 |
28 | elapsing | 11 |
29 | euro-quality-of-life | 1 |
30 | grazing/standing | 1 |
31 | hall-walk-test | 1 |
32 | holters | 2 |
33 | iii-complexes | 1 |
34 | indo-treated | 1 |
35 | integrales | 1 |
36 | internals | 3 |
37 | interval-1.8 | 1 |
38 | interval-3.27 | 1 |
39 | interval.28 | 1 |
40 | interval.37 | 1 |
41 | interval.studies | 1 |
42 | interval/ | 1 |
43 | interval1.16 | 1 |
44 | interval:13.2 | 1 |
45 | interval:24 | 1 |
46 | interval=-0.08 | 1 |
47 | interval=-0.10 | 1 |
48 | interval=-0.29 | 1 |
49 | interval=-1.9 | 1 |
50 | interval=-13.3 | 1 |
51 | interval=-16.6 | 1 |
52 | interval=-3.4-2.1 | 1 |
53 | interval=-3.64 | 1 |
54 | interval=-4.41 | 1 |
55 | interval=-6.40 | 1 |
56 | interval=0.15 | 1 |
57 | interval=0.17-0.98 | 1 |
58 | interval=0.21 | 1 |
59 | interval=0.212-0.950 | 1 |
60 | interval=0.35 | 1 |
61 | interval=0.38 | 1 |
62 | interval=0.41 | 1 |
63 | interval=0.46 | 1 |
64 | interval=0.65 | 1 |
65 | interval=0.73 | 1 |
66 | interval=0.75-3.25 | 1 |
67 | interval=0.76 | 1 |
68 | interval=0.78-0.97 | 1 |
69 | interval=0.85-1.59 | 1 |
70 | interval=0.9-6.0 | 1 |
71 | interval=1 | 1 |
72 | interval=1.00-1.25 | 1 |
73 | interval=1.02 | 1 |
74 | interval=1.03-1.29 | 1 |
75 | interval=1.03-14.42 | 1 |
76 | interval=1.1-4.1 | 1 |
77 | interval=1.12-1.26 | 1 |
78 | interval=1.13-3.86 | 1 |
79 | interval=1.20-7.47 | 1 |
80 | interval=1.26 | 1 |
81 | interval=1.27-7.79 | 1 |
82 | interval=1.3-5 | 1 |
83 | interval=1.39 | 1 |
84 | interval=1.92-50.19 | 1 |
85 | interval=11-15 | 1 |
86 | interval=2.0 | 1 |
87 | interval=2.3-5.0 | 1 |
88 | interval=2.53-9.64 | 1 |
89 | interval=3 | 1 |
90 | interval=3.9 | 1 |
91 | interval=4.0 | 1 |
92 | interval=4.3 | 1 |
93 | interval=95 | 1 |
94 | intervals | 11,430 |
95 | intervals=-2 | 1 |
96 | intervals=-3 | 1 |
97 | intervals=0.30-0.80 | 1 |
98 | intervals=1.03-1.40 | 1 |
99 | intralipid/heparin-infusion | 1 |
100 | intrerval | 1 |
101 | irvt | 1 |
102 | isoload | 1 |
103 | kt2442-r2 | 1 |
104 | leukocidine | 2 |
105 | level-0.08 | 1 |
106 | nap-takers | 1 |
107 | nitrogen-hyperoxia | 1 |
108 | pattern/axis | 1 |
109 | phonophobia-free | 1 |
110 | photophobia-free | 1 |
111 | placebo-electrolyte | 1 |
112 | post-tasting | 1 |
113 | post-water | 1 |
114 | postpremedication | 1 |
115 | posttenecteplase | 1 |
116 | predictabilities | 1 |
117 | prolastin®-c | 1 |
118 | pvts | 1 |
119 | risk-adjustors | 1 |
120 | rotation/day | 1 |
121 | rpe-session | 1 |
122 | stand-ups | 2 |
123 | sulfamerazine/trimethoprime | 1 |
124 | thigh/buttock | 1 |
125 | trials-exercise | 1 |
126 | ttp/ttf | 1 |
127 | u-100 | 1 |
128 | vb_efas_gec-efs_3 | 1 |
129 | walk/jog | 1 |
130 | weigh-ins | 3 |
131 | wii-intervention | 1 |
1 | 1'-o- | 1 |
2 | interval/ | 1 |
3 | interval=2.0 | 1 |
4 | interval=4.0 | 1 |
5 | interval=2.3-5.0 | 1 |
6 | interval=0.9-6.0 | 1 |
7 | u-100 | 1 |
8 | interval=-0.10 | 1 |
9 | intervals=1.03-1.40 | 1 |
10 | interval=-6.40 | 1 |
11 | interval=0.212-0.950 | 1 |
12 | intervals=0.30-0.80 | 1 |
13 | interval=-3.4-2.1 | 1 |
14 | interval=1.1-4.1 | 1 |
15 | interval=0.21 | 1 |
16 | interval=0.41 | 1 |
17 | interval=-4.41 | 1 |
18 | interval=1 | 1 |
19 | intervals=-2 | 1 |
20 | interval:13.2 | 1 |
21 | interval=1.02 | 1 |
22 | interval=1.03-14.42 | 1 |
23 | kt2442-r2 | 1 |
24 | intervals=-3 | 1 |
25 | interval=-13.3 | 1 |
26 | interval=4.3 | 1 |
27 | interval=0.73 | 1 |
28 | interval=3 | 1 |
29 | vb_efas_gec-efs_3 | 1 |
30 | interval:24 | 1 |
31 | interval=-3.64 | 1 |
32 | interval=2.53-9.64 | 1 |
33 | interval=1.3-5 | 1 |
34 | interval=11-15 | 1 |
35 | interval=0.15 | 1 |
36 | interval=1.00-1.25 | 1 |
37 | interval=0.75-3.25 | 1 |
38 | interval=0.35 | 1 |
39 | interval=0.65 | 1 |
40 | interval=95 | 1 |
41 | interval=-16.6 | 1 |
42 | interval1.16 | 1 |
43 | ca125/muc16 | 1 |
44 | interval=1.12-1.26 | 1 |
45 | interval=1.26 | 1 |
46 | interval=0.46 | 1 |
47 | interval=0.76 | 1 |
48 | interval=1.13-3.86 | 1 |
49 | interval-3.27 | 1 |
50 | interval.37 | 1 |
51 | interval=1.20-7.47 | 1 |
52 | interval=0.78-0.97 | 1 |
53 | interval-1.8 | 1 |
54 | interval=-0.08 | 1 |
55 | level-0.08 | 1 |
56 | interval.28 | 1 |
57 | interval=0.38 | 1 |
58 | interval=0.17-0.98 | 1 |
59 | interval=-1.9 | 1 |
60 | interval=3.9 | 1 |
61 | interval=1.92-50.19 | 1 |
62 | interval=-0.29 | 1 |
63 | interval=1.03-1.29 | 1 |
64 | interval=1.39 | 1 |
65 | interval=0.85-1.59 | 1 |
66 | interval=1.27-7.79 | 1 |
67 | nitrogen-hyperoxia | 1 |
68 | prolastin®-c | 1 |
69 | 'cc | 1 |
70 | acaloric | 1 |
71 | 'tc | 1 |
72 | isoload | 1 |
73 | indo-treated | 1 |
74 | dexamethasone.experience | 1 |
75 | phonophobia-free | 1 |
76 | photophobia-free | 1 |
77 | euro-quality-of-life | 1 |
78 | sulfamerazine/trimethoprime | 1 |
79 | leukocidine | 2 |
80 | edta-saline | 1 |
81 | alpha-pregnan-3-one | 1 |
82 | posttenecteplase | 1 |
83 | trials-exercise | 1 |
84 | alendronate/risedronate | 3 |
85 | placebo-electrolyte | 1 |
86 | acid-schiff | 31 |
87 | acid/schiff | 1 |
88 | ttp/ttf | 1 |
89 | grazing/standing | 1 |
90 | ebm-teaching | 1 |
91 | elapsing | 11 |
92 | cytokine/fasting | 1 |
93 | post-tasting | 1 |
94 | walk/jog | 1 |
95 | thigh/buttock | 1 |
96 | classes/week | 1 |
97 | drinking-in-dark | 1 |
98 | intrerval | 1 |
99 | amaronitidin | 1 |
100 | rpe-session | 1 |
101 | intralipid/heparin-infusion | 1 |
102 | postpremedication | 1 |
103 | wii-intervention | 1 |
104 | ca-al-co | 2 |
105 | post-water | 1 |
106 | acid-methenamine-silver | 1 |
107 | auc-gir | 1 |
108 | dyspneas | 1 |
109 | interval.studies | 1 |
110 | asynergies | 1 |
111 | predictabilities | 1 |
112 | integrales | 1 |
113 | 253,44±51,51minutes | 1 |
114 | iii-complexes | 1 |
115 | pattern/axis | 1 |
116 | internals | 3 |
117 | intervals | 11,430 |
118 | weigh-ins | 3 |
119 | stand-ups | 2 |
120 | nap-takers | 1 |
121 | choosers | 4 |
122 | holters | 2 |
123 | risk-adjustors | 1 |
124 | 201tl-stress | 1 |
125 | pvts | 1 |
126 | at.lantus | 1 |
127 | hall-walk-test | 1 |
128 | irvt | 1 |
129 | 0–t | 1 |
130 | rotation/day | 1 |
131 | disease-history | 1 |